Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

ARQT

Get informed when a big investor buys or sells

+ Follow
Market Cap$3.56B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Arcutis Biotherapeutics IncArcutis Biotherapeutics Inc-1483.9--1%9.30.1
$-28.99

Current Fair Value

203.9% downside

Overvalued by 203.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$3.56 Billion
Enterprise Value$3.54 Billion
Dividend Yield$- (-)
Earnings per Share$-0.13
Beta1.48
Outstanding Shares129,365,000

Return

Return on Equity-1.25%ROE
Return on Assets-0.52%
Return on Invested Capital3.31%

Valuation & Multiples

P/E Ratio-1483.85P/E Ratio
PEG2701.44PEG
Price to Sales9.3Price to Sales
Price to Book Ratio27.9Price to Book Ratio
Enterprise Value to Revenue8.52
Enterprise Value to EBIT360.59
Enterprise Value to Net Income-1491
Total Debt to Enterprise0
Debt to Equity0.07Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 19, 2026
EPS Estimate
$-0.05
Average shareholder expectation
Revenue Estimate
$102.21 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 5, 2026
EPS Estimate
$0.07
Average shareholder expectation
Revenue Estimate
$118.85 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000 24.58%
Total Calls- 100.00%
Total Puts- 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %1.24% 102.67%
Total Invested$42.08M 98.65%
Investors Holding19 258.00%

ESG Score

No data

About Arcutis Biotherapeutics Inc

Relevant Senate Committees

Finance

Drives corporate valuations through tax policy, and its control over entitlement spending (Medicare/Medicaid) directly impacts a significant portion of the pharmaceutical market.

Appropriations

Controls federal spending allocations, which directly impacts funding for agencies like the FDA, NIH, and VA healthcare, thereby influencing research grants and government procurement of pharmaceuticals.

Health, Education, Labor, and Pensions

Directly regulates the FDA (drug approval is essential for ARQT) and NIH (critical for R&D funding), making it highly influential over the pharmaceutical and biotech sectors.

Judiciary

Directly impacts pharmaceutical companies through oversight of intellectual property (patent protection is vital for pharma) and antitrust enforcement regarding mergers and and competition.